 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Lantheus Holdings, Inc. (LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. 
It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.
The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.
It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer.
The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices.
Shares have formed a bullish "flag" following the company's latest quarterly report. On February 23rd, LNTH reported Quarter December 2022 earnings of $1.37 per share on revenue of $263.2 million. The consensus earnings estimate was $0.96 per share on revenue of $244.6 million. Revenue grew 103.1% on a year-over-year basis.
Guided Higher: The company said it expects first quarter non-GAAP earnings of $1.28 to $1.32 per share on revenue of $280.0 million to $285.0 million. The prior consensus earnings estimate was $1.09 per share on revenue of $252.39 million for the quarter ending March 31, 2023. The company said it expects 2023 non-GAAP earnings of $4.95 to $5.10 per share on revenue of $1.14 billion to $1.16 billion. The prior consensus earnings estimate was $4.36 per share on revenue of $1.03 billion for the year ending December 31, 2023.
Higher share prices are expected.
Entry Point: $74.75
Stop Loss: $71.00
Trading Range: $47.46 to $87.47
Target Price: $82.00
LNTH closed at $71.00
